MedTrace Logo

Pharmacist Intervention to Improve Smoking Cessation

NCT06943287 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-04-17

No results posted yet for this study

Summary

The goal of this study is to assess the effectiveness of a remote pharmacist intervention to help smokers quit.

The main questions it aims to answer are:

* Will smokers being screened for lung cancer with low-radiation-level chest computed tomography (CT) be willing to participate in this study and talk to the pharmacist about smoking cessation?
* Will those in the intervention group be more likely to report smoking cessation than those in the control group.

Participants in the intervention group will be asked to complete a baseline survey; speak with a pharmacist via phone call at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, and 12 weeks; and complete an exit survey.

Participants in the control group will be asked to complete a baseline survey and an exit survey.

Conditions

  • Smoking Cessation

Interventions

BEHAVIORAL

Pharmacist Intervention

If the patient is randomized to the intervention group, they will complete a series of phone calls with the research pharmacist. These will occur at baseline (within 1 to 2 days of enrollment), 2-weeks, 4-weeks, 6-weeks, 8-weeks, 10-weeks, and 12-weeks. During these calls, the research pharmacist will ask the patient about any past quit attempts; when they had their last cigarette; if they have been prescribed any cessation medications; if they have picked up their medication; if they have started the medication; they will assess their stage of change for quitting; discuss pros, cons, and barriers of quitting; behavioral responses to triggers/urges; and make any necessary nicotine replacement therapy (NRT; i.e., nicotine patches, gums, lozenges, inhalers, and/or nasal sprays) changes. Each call is expected to take 20-30 minutes.

Sponsors & Collaborators

  • University of Iowa

    lead OTHER

Principal Investigators

  • Jacob E Simmering, PhD · University of Iowa

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-11
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06943287 on ClinicalTrials.gov